课题基金 / 基金详情

Biomarkers of Replication and Injury in HBV/HIV

Biomarkers of Replication and Injury in HBV/HIV
HBV/HIV 复制和损伤的生物标志物
批准号:
10326569
负责人:
KENNETH E SHERMAN
金额:
$23.67万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-07-12 至 2023-06-30

项目摘要

项目成果

KENNETH E SHERMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Abstract Hepatitis B virus (HBV) is a serious global health concern. In those with HIV it is associated with increased risk of chronicity after acute infection, and increased rates of liver-associated mortality. The field of HBV treatment is undergoing evolution, changing focus from HBV DNA suppression to functional and complete HBV cure. Biomarkers that provide clear guidance regarding prediction, treatment outcome and accurate information regarding liver injury are limited. Though research use of newer HBV biomarkers including pgRNA, quantitative surface antigen and HBV core-related antigen has accelerated in the last year, very limited data exists with regard to their use and utility among persons living with HIV (PLWH). In this Exploratory R21 application we propose to evaluate the potential role of several biomarkers that have not been previously characterized in those with HBV/HIV coinfection. HBV pgRNA represents a transcript of the cccDNA minichromosome that is central to development and perpetuation of HBV chronicity. Using 3 complementary cohorts of PLWH, we will evaluate the association of these biomarkers with CD4 count, HIV viral load and other demographic and serologic HBV markers stratified by categorical natural history replicative stages of HBV disease. In one AIDS Clinical Trials Group (ACTG) cohort, we will examine longitudinal changes in these biomarkers associated with initiation of nucleoside therapy. Our laboratory has recently implemented use of a new blood-based cccDNA assay which will be utilized in conjunction with the pgRNA assays to determine the frequency and proportion of gene silencing. Using novel liver-derived exosome markers of liver injury we will explore whether gene silencing is associated with lower levels of liver injury than are identified with more traditional markers of response such as serum ALT. This characterization will provide key information that may inform future cure strategies for HBV, in PLWH which are being studied within the ACTG and elsewhere.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biomarkers of Replication and Injury in HBV/HIV
  • 批准号:
    10449351
  • 项目类别:
  • 资助金额:
    $20.73万
  • 财政年份:
    2021
  • 负责人:
    KENNETH E SHERMAN
  • 依托单位:
Hepatitis E in HIV-Infected Patients
  • 批准号:
    9335720
  • 项目类别:
  • 资助金额:
    $27.5万
  • 财政年份:
    2015
  • 负责人:
    KENNETH E SHERMAN
  • 依托单位:
Hepatitis E in HIV-Infected Patients
  • 批准号:
    9049750
  • 项目类别:
  • 资助金额:
    $27.5万
  • 财政年份:
    2015
  • 负责人:
    KENNETH E SHERMAN
  • 依托单位:
Viral kinetic models of HCV clearance in hemophiliacs treated with telaprevir
  • 批准号:
    8472526
  • 项目类别:
  • 资助金额:
    $34.06万
  • 财政年份:
    2012
  • 负责人:
    KENNETH E SHERMAN
  • 依托单位:
海外基金